Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Corcept Therapeutics Incorporated”

120 pharma patents match "Corcept Therapeutics Incorporated" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 120
Index total 30,257
Page 1 / 5

Quick answer

This filtered view shows 120 pharmaceutical patents matching "Corcept Therapeutics Incorporated" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

120 results for “Corcept Therapeutics Incorporated” · 30,257 patents in full index Clear search

  1. US 12370175

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  2. US 12370188

    Formulations of dazucorilant, a glucocorticoid receptor modulator

    Corcept Therapeutics Incorporated · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  3. US 12336985

    Methods for shrinking pituitary tumors

    Corcept Therapeutics Incorporated · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  4. US 12290551

    Methods for imaging and treatment of somatostatin-receptor positive tumors

    Corcept Therapeutics Incorporated · Granted May 6, 2025 · Expires May 1, 2045

    granted
  5. US 12285425

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted Apr 29, 2025 · Expires Apr 24, 2045

    granted
  6. US 12263169

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Apr 1, 2025 · Expires Mar 27, 2045

    granted
  7. US 12226412

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  8. US 12226417

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  9. US 12171760

    Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

    Corcept Therapeutics Incorporated · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  10. US 12152028

    Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Nov 26, 2024 · Expires Nov 21, 2044

    granted
  11. US 12144812

    Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Nov 19, 2024 · Expires Nov 14, 2044

    granted
  12. US 12139486

    Octahydro fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  13. US 12109272

    Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers

    Corcept Therapeutics Incorporated · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  14. US 12102642

    Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  15. US 12097210

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Corcept Therapeutics Incorporated · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  16. US 12098141

    Bicyclic indazole glucocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  17. US 12097192

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Corcept Therapeutics Incorporated · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  18. US 12098144

    Piperazine indazole glucocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  19. US 12018001

    Pyrimidine cyclohexenyl glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  20. US 12005055

    Methods for shrinking pituitary tumors

    Corcept Therapeutics Incorporated · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  21. US 11969435

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Corcept Therapeutics Incorporated · Granted Apr 30, 2024 · Expires Apr 25, 2044

    granted
  22. US 11944617

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

    Corcept Therapeutics Incorporated · Granted Apr 2, 2024 · Expires Mar 28, 2044

    granted
  23. US 11925626

    Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

    Corcept Therapeutics Incorporated · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  24. US 11903945

    Methods of treating antipsychotic-induced weight gain with miricorilant

    Corcept Therapeutics Incorporated · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted